Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 6 publications
eIF4A controls translation of estrogen receptor alpha and is a therapeutic target in advanced breast cancer.
Journal: Proceedings of the National Academy of Sciences of the United States of America
Published: July 21, 2025
eIF4A controls translation of estrogen receptor alpha and is a therapeutic target in advanced breast cancer.
Journal: bioRxiv : the preprint server for biology
Published: May 20, 2024
Denosumab versus zoledronic acid in bone disease treatment of newly diagnosed multiple myeloma: an international, double-blind, double-dummy, randomised, controlled, phase 3 study.
Journal: The Lancet. Oncology
Published: September 21, 2017
An Observational Study of Concomitant Use of Emerging Therapies and Denosumab or Zoledronic Acid in Prostate Cancer.
Journal: Clinical therapeutics
Published: September 09, 2017
Changes in Bone Turnover Marker Levels and Clinical Outcomes in Patients with Advanced Cancer and Bone Metastases Treated with Bone Antiresorptive Agents.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: December 22, 2015
Adjuvant denosumab in breast cancer (ABCSG-18): a multicentre, randomised, double-blind, placebo-controlled trial.
Journal: Lancet (London, England)
Published: June 05, 2015
Showing 1-6 of 6
Last Updated: 09/26/2026